nodes	percent_of_prediction	percent_of_DWPC	metapath
Zidovudine—SLC22A2—Cytarabine—lymphatic system cancer	0.13	0.165	CbGbCtD
Zidovudine—ABCG2—Teniposide—lymphatic system cancer	0.0948	0.12	CbGbCtD
Zidovudine—ABCG2—Mitoxantrone—lymphatic system cancer	0.0663	0.0839	CbGbCtD
Zidovudine—SLC22A11—Methotrexate—lymphatic system cancer	0.0552	0.0698	CbGbCtD
Zidovudine—SLC22A7—Methotrexate—lymphatic system cancer	0.0526	0.0665	CbGbCtD
Zidovudine—ABCC4—Methotrexate—lymphatic system cancer	0.0514	0.065	CbGbCtD
Zidovudine—ABCG2—Vincristine—lymphatic system cancer	0.0456	0.0577	CbGbCtD
Zidovudine—CYP2C19—Teniposide—lymphatic system cancer	0.0424	0.0536	CbGbCtD
Zidovudine—CYP2C9—Teniposide—lymphatic system cancer	0.0352	0.0445	CbGbCtD
Zidovudine—SLC22A8—Methotrexate—lymphatic system cancer	0.0321	0.0406	CbGbCtD
Zidovudine—ABCG2—Methotrexate—lymphatic system cancer	0.0276	0.0349	CbGbCtD
Zidovudine—ABCB1—Mitoxantrone—lymphatic system cancer	0.0239	0.0302	CbGbCtD
Zidovudine—SLC22A6—Methotrexate—lymphatic system cancer	0.0224	0.0283	CbGbCtD
Zidovudine—CYP3A4—Cytarabine—lymphatic system cancer	0.0208	0.0263	CbGbCtD
Zidovudine—CYP3A4—Teniposide—lymphatic system cancer	0.0205	0.0259	CbGbCtD
Zidovudine—ALB—Methotrexate—lymphatic system cancer	0.019	0.0241	CbGbCtD
Zidovudine—ABCB1—Vincristine—lymphatic system cancer	0.0165	0.0208	CbGbCtD
Zidovudine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0143	0.0181	CbGbCtD
Zidovudine—ABCB1—Methotrexate—lymphatic system cancer	0.00996	0.0126	CbGbCtD
Zidovudine—CYP3A4—Vincristine—lymphatic system cancer	0.00986	0.0125	CbGbCtD
Zidovudine—TK1—Azacitidine—Fludarabine—lymphatic system cancer	0.00253	0.514	CbGdCrCtD
Zidovudine—TK1—Azacitidine—Cytarabine—lymphatic system cancer	0.00239	0.486	CbGdCrCtD
Zidovudine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000454	0.00222	CcSEcCtD
Zidovudine—Fatigue—Fludarabine—lymphatic system cancer	0.000454	0.00222	CcSEcCtD
Zidovudine—Constipation—Fludarabine—lymphatic system cancer	0.00045	0.0022	CcSEcCtD
Zidovudine—Pain—Fludarabine—lymphatic system cancer	0.00045	0.0022	CcSEcCtD
Zidovudine—Vasculitis—Methotrexate—lymphatic system cancer	0.000448	0.00219	CcSEcCtD
Zidovudine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.000447	0.00219	CcSEcCtD
Zidovudine—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000445	0.00218	CcSEcCtD
Zidovudine—Urethral disorder—Vincristine—lymphatic system cancer	0.000444	0.00217	CcSEcCtD
Zidovudine—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000442	0.00216	CcSEcCtD
Zidovudine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000441	0.00216	CcSEcCtD
Zidovudine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000439	0.00215	CcSEcCtD
Zidovudine—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000438	0.00214	CcSEcCtD
Zidovudine—Anaemia—Bleomycin—lymphatic system cancer	0.000437	0.00214	CcSEcCtD
Zidovudine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000434	0.00212	CcSEcCtD
Zidovudine—Asthenia—Teniposide—lymphatic system cancer	0.00043	0.0021	CcSEcCtD
Zidovudine—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.000427	0.00209	CcSEcCtD
Zidovudine—Malaise—Bleomycin—lymphatic system cancer	0.000426	0.00209	CcSEcCtD
Zidovudine—Pruritus—Teniposide—lymphatic system cancer	0.000424	0.00207	CcSEcCtD
Zidovudine—Leukopenia—Bleomycin—lymphatic system cancer	0.000423	0.00207	CcSEcCtD
Zidovudine—Cystitis—Methotrexate—lymphatic system cancer	0.000422	0.00207	CcSEcCtD
Zidovudine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00042	0.00206	CcSEcCtD
Zidovudine—Body temperature increased—Fludarabine—lymphatic system cancer	0.000416	0.00204	CcSEcCtD
Zidovudine—Mental disorder—Carmustine—lymphatic system cancer	0.000415	0.00203	CcSEcCtD
Zidovudine—Malnutrition—Carmustine—lymphatic system cancer	0.000413	0.00202	CcSEcCtD
Zidovudine—Erythema—Carmustine—lymphatic system cancer	0.000413	0.00202	CcSEcCtD
Zidovudine—Cough—Bleomycin—lymphatic system cancer	0.000413	0.00202	CcSEcCtD
Zidovudine—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.000411	0.00201	CcSEcCtD
Zidovudine—Diarrhoea—Teniposide—lymphatic system cancer	0.00041	0.00201	CcSEcCtD
Zidovudine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000408	0.002	CcSEcCtD
Zidovudine—Chest pain—Bleomycin—lymphatic system cancer	0.000403	0.00197	CcSEcCtD
Zidovudine—Myalgia—Bleomycin—lymphatic system cancer	0.000403	0.00197	CcSEcCtD
Zidovudine—Back pain—Carmustine—lymphatic system cancer	0.000399	0.00195	CcSEcCtD
Zidovudine—Discomfort—Bleomycin—lymphatic system cancer	0.000398	0.00195	CcSEcCtD
Zidovudine—Mental disorder—Vincristine—lymphatic system cancer	0.000397	0.00194	CcSEcCtD
Zidovudine—Chills—Mitoxantrone—lymphatic system cancer	0.000396	0.00194	CcSEcCtD
Zidovudine—Bladder pain—Methotrexate—lymphatic system cancer	0.000395	0.00194	CcSEcCtD
Zidovudine—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000395	0.00194	CcSEcCtD
Zidovudine—Urine output increased—Methotrexate—lymphatic system cancer	0.000395	0.00194	CcSEcCtD
Zidovudine—Gynaecomastia—Methotrexate—lymphatic system cancer	0.000391	0.00192	CcSEcCtD
Zidovudine—Confusional state—Bleomycin—lymphatic system cancer	0.000389	0.0019	CcSEcCtD
Zidovudine—Tremor—Carmustine—lymphatic system cancer	0.000387	0.00189	CcSEcCtD
Zidovudine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000386	0.00189	CcSEcCtD
Zidovudine—Oedema—Bleomycin—lymphatic system cancer	0.000386	0.00189	CcSEcCtD
Zidovudine—Erythema—Mitoxantrone—lymphatic system cancer	0.000384	0.00188	CcSEcCtD
Zidovudine—Anaemia—Carmustine—lymphatic system cancer	0.000382	0.00187	CcSEcCtD
Zidovudine—Back pain—Vincristine—lymphatic system cancer	0.000381	0.00187	CcSEcCtD
Zidovudine—Vomiting—Teniposide—lymphatic system cancer	0.000381	0.00186	CcSEcCtD
Zidovudine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000378	0.00185	CcSEcCtD
Zidovudine—Asthenia—Fludarabine—lymphatic system cancer	0.000378	0.00185	CcSEcCtD
Zidovudine—Rash—Teniposide—lymphatic system cancer	0.000378	0.00185	CcSEcCtD
Zidovudine—Dermatitis—Teniposide—lymphatic system cancer	0.000377	0.00185	CcSEcCtD
Zidovudine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000376	0.00184	CcSEcCtD
Zidovudine—Headache—Teniposide—lymphatic system cancer	0.000375	0.00184	CcSEcCtD
Zidovudine—Pruritus—Fludarabine—lymphatic system cancer	0.000372	0.00182	CcSEcCtD
Zidovudine—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000372	0.00182	CcSEcCtD
Zidovudine—Back pain—Mitoxantrone—lymphatic system cancer	0.000371	0.00182	CcSEcCtD
Zidovudine—Leukopenia—Carmustine—lymphatic system cancer	0.000369	0.00181	CcSEcCtD
Zidovudine—Anorexia—Bleomycin—lymphatic system cancer	0.000368	0.0018	CcSEcCtD
Zidovudine—Anaemia—Vincristine—lymphatic system cancer	0.000364	0.00178	CcSEcCtD
Zidovudine—Polyuria—Methotrexate—lymphatic system cancer	0.000362	0.00177	CcSEcCtD
Zidovudine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00036	0.00176	CcSEcCtD
Zidovudine—Convulsion—Carmustine—lymphatic system cancer	0.000358	0.00175	CcSEcCtD
Zidovudine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000356	0.00174	CcSEcCtD
Zidovudine—Nausea—Teniposide—lymphatic system cancer	0.000356	0.00174	CcSEcCtD
Zidovudine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000355	0.00174	CcSEcCtD
Zidovudine—Vertigo—Vincristine—lymphatic system cancer	0.000354	0.00173	CcSEcCtD
Zidovudine—Leukopenia—Vincristine—lymphatic system cancer	0.000353	0.00173	CcSEcCtD
Zidovudine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000352	0.00172	CcSEcCtD
Zidovudine—Myalgia—Carmustine—lymphatic system cancer	0.000351	0.00172	CcSEcCtD
Zidovudine—Chest pain—Carmustine—lymphatic system cancer	0.000351	0.00172	CcSEcCtD
Zidovudine—Anxiety—Carmustine—lymphatic system cancer	0.00035	0.00171	CcSEcCtD
Zidovudine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000347	0.0017	CcSEcCtD
Zidovudine—Malaise—Mitoxantrone—lymphatic system cancer	0.000346	0.00169	CcSEcCtD
Zidovudine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000344	0.00168	CcSEcCtD
Zidovudine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000344	0.00168	CcSEcCtD
Zidovudine—Convulsion—Vincristine—lymphatic system cancer	0.000341	0.00167	CcSEcCtD
Zidovudine—Confusional state—Carmustine—lymphatic system cancer	0.00034	0.00166	CcSEcCtD
Zidovudine—Oedema—Carmustine—lymphatic system cancer	0.000337	0.00165	CcSEcCtD
Zidovudine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000335	0.00164	CcSEcCtD
Zidovudine—Myalgia—Vincristine—lymphatic system cancer	0.000335	0.00164	CcSEcCtD
Zidovudine—Cough—Mitoxantrone—lymphatic system cancer	0.000335	0.00164	CcSEcCtD
Zidovudine—Vomiting—Fludarabine—lymphatic system cancer	0.000335	0.00164	CcSEcCtD
Zidovudine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000332	0.00163	CcSEcCtD
Zidovudine—Rash—Fludarabine—lymphatic system cancer	0.000332	0.00162	CcSEcCtD
Zidovudine—Dermatitis—Fludarabine—lymphatic system cancer	0.000332	0.00162	CcSEcCtD
Zidovudine—Pain—Bleomycin—lymphatic system cancer	0.00033	0.00162	CcSEcCtD
Zidovudine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00033	0.00161	CcSEcCtD
Zidovudine—Headache—Fludarabine—lymphatic system cancer	0.00033	0.00161	CcSEcCtD
Zidovudine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000327	0.0016	CcSEcCtD
Zidovudine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000327	0.0016	CcSEcCtD
Zidovudine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000327	0.0016	CcSEcCtD
Zidovudine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000326	0.00159	CcSEcCtD
Zidovudine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000323	0.00158	CcSEcCtD
Zidovudine—Oedema—Vincristine—lymphatic system cancer	0.000322	0.00157	CcSEcCtD
Zidovudine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000322	0.00157	CcSEcCtD
Zidovudine—Anorexia—Carmustine—lymphatic system cancer	0.000321	0.00157	CcSEcCtD
Zidovudine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000318	0.00156	CcSEcCtD
Zidovudine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000316	0.00155	CcSEcCtD
Zidovudine—Nervous system disorder—Vincristine—lymphatic system cancer	0.000315	0.00154	CcSEcCtD
Zidovudine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000315	0.00154	CcSEcCtD
Zidovudine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000313	0.00153	CcSEcCtD
Zidovudine—Oedema—Mitoxantrone—lymphatic system cancer	0.000313	0.00153	CcSEcCtD
Zidovudine—Nausea—Fludarabine—lymphatic system cancer	0.000313	0.00153	CcSEcCtD
Zidovudine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000311	0.00152	CcSEcCtD
Zidovudine—Shock—Mitoxantrone—lymphatic system cancer	0.000308	0.00151	CcSEcCtD
Zidovudine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000307	0.0015	CcSEcCtD
Zidovudine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000307	0.0015	CcSEcCtD
Zidovudine—Urticaria—Bleomycin—lymphatic system cancer	0.000307	0.0015	CcSEcCtD
Zidovudine—Anorexia—Vincristine—lymphatic system cancer	0.000307	0.0015	CcSEcCtD
Zidovudine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000305	0.00149	CcSEcCtD
Zidovudine—Insomnia—Carmustine—lymphatic system cancer	0.000305	0.00149	CcSEcCtD
Zidovudine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000304	0.00149	CcSEcCtD
Zidovudine—Irritability—Methotrexate—lymphatic system cancer	0.000303	0.00148	CcSEcCtD
Zidovudine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000303	0.00148	CcSEcCtD
Zidovudine—Paraesthesia—Carmustine—lymphatic system cancer	0.000303	0.00148	CcSEcCtD
Zidovudine—Mood swings—Methotrexate—lymphatic system cancer	0.000301	0.00147	CcSEcCtD
Zidovudine—Dyspnoea—Carmustine—lymphatic system cancer	0.0003	0.00147	CcSEcCtD
Zidovudine—Somnolence—Carmustine—lymphatic system cancer	0.000299	0.00147	CcSEcCtD
Zidovudine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000299	0.00146	CcSEcCtD
Zidovudine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000293	0.00143	CcSEcCtD
Zidovudine—Decreased appetite—Carmustine—lymphatic system cancer	0.000293	0.00143	CcSEcCtD
Zidovudine—Insomnia—Vincristine—lymphatic system cancer	0.000291	0.00142	CcSEcCtD
Zidovudine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000291	0.00142	CcSEcCtD
Zidovudine—Paraesthesia—Vincristine—lymphatic system cancer	0.000289	0.00141	CcSEcCtD
Zidovudine—Pain—Carmustine—lymphatic system cancer	0.000288	0.00141	CcSEcCtD
Zidovudine—Constipation—Carmustine—lymphatic system cancer	0.000288	0.00141	CcSEcCtD
Zidovudine—Breast disorder—Methotrexate—lymphatic system cancer	0.000287	0.0014	CcSEcCtD
Zidovudine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000286	0.0014	CcSEcCtD
Zidovudine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000285	0.0014	CcSEcCtD
Zidovudine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000281	0.00138	CcSEcCtD
Zidovudine—Decreased appetite—Vincristine—lymphatic system cancer	0.00028	0.00137	CcSEcCtD
Zidovudine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000279	0.00137	CcSEcCtD
Zidovudine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000278	0.00136	CcSEcCtD
Zidovudine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000278	0.00136	CcSEcCtD
Zidovudine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000278	0.00136	CcSEcCtD
Zidovudine—Fatigue—Vincristine—lymphatic system cancer	0.000277	0.00136	CcSEcCtD
Zidovudine—Asthenia—Bleomycin—lymphatic system cancer	0.000277	0.00136	CcSEcCtD
Zidovudine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000276	0.00135	CcSEcCtD
Zidovudine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000275	0.00135	CcSEcCtD
Zidovudine—Constipation—Vincristine—lymphatic system cancer	0.000275	0.00135	CcSEcCtD
Zidovudine—Pain—Vincristine—lymphatic system cancer	0.000275	0.00135	CcSEcCtD
Zidovudine—Pruritus—Bleomycin—lymphatic system cancer	0.000273	0.00134	CcSEcCtD
Zidovudine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000272	0.00133	CcSEcCtD
Zidovudine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00027	0.00132	CcSEcCtD
Zidovudine—Pancreatitis—Methotrexate—lymphatic system cancer	0.000269	0.00132	CcSEcCtD
Zidovudine—Constipation—Mitoxantrone—lymphatic system cancer	0.000268	0.00131	CcSEcCtD
Zidovudine—Pain—Mitoxantrone—lymphatic system cancer	0.000268	0.00131	CcSEcCtD
Zidovudine—Abdominal pain—Carmustine—lymphatic system cancer	0.000266	0.0013	CcSEcCtD
Zidovudine—Body temperature increased—Carmustine—lymphatic system cancer	0.000266	0.0013	CcSEcCtD
Zidovudine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000263	0.00129	CcSEcCtD
Zidovudine—Pancytopenia—Methotrexate—lymphatic system cancer	0.000261	0.00128	CcSEcCtD
Zidovudine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000258	0.00126	CcSEcCtD
Zidovudine—Dysuria—Methotrexate—lymphatic system cancer	0.000257	0.00126	CcSEcCtD
Zidovudine—Neutropenia—Methotrexate—lymphatic system cancer	0.000257	0.00126	CcSEcCtD
Zidovudine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000256	0.00125	CcSEcCtD
Zidovudine—Body temperature increased—Vincristine—lymphatic system cancer	0.000254	0.00124	CcSEcCtD
Zidovudine—Abdominal pain—Vincristine—lymphatic system cancer	0.000254	0.00124	CcSEcCtD
Zidovudine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000249	0.00122	CcSEcCtD
Zidovudine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000248	0.00121	CcSEcCtD
Zidovudine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000248	0.00121	CcSEcCtD
Zidovudine—Vomiting—Bleomycin—lymphatic system cancer	0.000245	0.0012	CcSEcCtD
Zidovudine—Rash—Bleomycin—lymphatic system cancer	0.000243	0.00119	CcSEcCtD
Zidovudine—Dermatitis—Bleomycin—lymphatic system cancer	0.000243	0.00119	CcSEcCtD
Zidovudine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000243	0.00119	CcSEcCtD
Zidovudine—Asthenia—Carmustine—lymphatic system cancer	0.000242	0.00118	CcSEcCtD
Zidovudine—Stomatitis—Methotrexate—lymphatic system cancer	0.000238	0.00117	CcSEcCtD
Zidovudine—Sweating—Methotrexate—lymphatic system cancer	0.000235	0.00115	CcSEcCtD
Zidovudine—Haematuria—Methotrexate—lymphatic system cancer	0.000233	0.00114	CcSEcCtD
Zidovudine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000231	0.00113	CcSEcCtD
Zidovudine—Epistaxis—Methotrexate—lymphatic system cancer	0.000231	0.00113	CcSEcCtD
Zidovudine—Asthenia—Vincristine—lymphatic system cancer	0.000231	0.00113	CcSEcCtD
Zidovudine—Diarrhoea—Carmustine—lymphatic system cancer	0.00023	0.00113	CcSEcCtD
Zidovudine—Nausea—Bleomycin—lymphatic system cancer	0.000229	0.00112	CcSEcCtD
Zidovudine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000228	0.00112	CcSEcCtD
Zidovudine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000225	0.0011	CcSEcCtD
Zidovudine—Dizziness—Carmustine—lymphatic system cancer	0.000223	0.00109	CcSEcCtD
Zidovudine—Diarrhoea—Vincristine—lymphatic system cancer	0.00022	0.00108	CcSEcCtD
Zidovudine—Hepatitis—Methotrexate—lymphatic system cancer	0.00022	0.00107	CcSEcCtD
Zidovudine—Pharyngitis—Methotrexate—lymphatic system cancer	0.000218	0.00107	CcSEcCtD
Zidovudine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000217	0.00106	CcSEcCtD
Zidovudine—Urethral disorder—Methotrexate—lymphatic system cancer	0.000215	0.00105	CcSEcCtD
Zidovudine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000214	0.00105	CcSEcCtD
Zidovudine—Vomiting—Carmustine—lymphatic system cancer	0.000214	0.00105	CcSEcCtD
Zidovudine—Dizziness—Vincristine—lymphatic system cancer	0.000213	0.00104	CcSEcCtD
Zidovudine—Rash—Carmustine—lymphatic system cancer	0.000212	0.00104	CcSEcCtD
Zidovudine—Dermatitis—Carmustine—lymphatic system cancer	0.000212	0.00104	CcSEcCtD
Zidovudine—Headache—Carmustine—lymphatic system cancer	0.000211	0.00103	CcSEcCtD
Zidovudine—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000208	0.00102	CcSEcCtD
Zidovudine—Vomiting—Vincristine—lymphatic system cancer	0.000204	0.001	CcSEcCtD
Zidovudine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000204	0.000998	CcSEcCtD
Zidovudine—Rash—Vincristine—lymphatic system cancer	0.000203	0.000992	CcSEcCtD
Zidovudine—Dermatitis—Vincristine—lymphatic system cancer	0.000203	0.000991	CcSEcCtD
Zidovudine—Headache—Vincristine—lymphatic system cancer	0.000201	0.000986	CcSEcCtD
Zidovudine—Nausea—Carmustine—lymphatic system cancer	0.0002	0.000979	CcSEcCtD
Zidovudine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000199	0.000975	CcSEcCtD
Zidovudine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000198	0.000969	CcSEcCtD
Zidovudine—Rash—Mitoxantrone—lymphatic system cancer	0.000197	0.000966	CcSEcCtD
Zidovudine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000197	0.000966	CcSEcCtD
Zidovudine—Chills—Methotrexate—lymphatic system cancer	0.000197	0.000965	CcSEcCtD
Zidovudine—Headache—Mitoxantrone—lymphatic system cancer	0.000196	0.00096	CcSEcCtD
Zidovudine—Mental disorder—Methotrexate—lymphatic system cancer	0.000192	0.000942	CcSEcCtD
Zidovudine—Erythema—Methotrexate—lymphatic system cancer	0.000191	0.000936	CcSEcCtD
Zidovudine—Malnutrition—Methotrexate—lymphatic system cancer	0.000191	0.000936	CcSEcCtD
Zidovudine—Nausea—Vincristine—lymphatic system cancer	0.000191	0.000935	CcSEcCtD
Zidovudine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000187	0.000916	CcSEcCtD
Zidovudine—Nausea—Mitoxantrone—lymphatic system cancer	0.000186	0.00091	CcSEcCtD
Zidovudine—Back pain—Methotrexate—lymphatic system cancer	0.000185	0.000905	CcSEcCtD
Zidovudine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000177	0.000868	CcSEcCtD
Zidovudine—Anaemia—Methotrexate—lymphatic system cancer	0.000177	0.000865	CcSEcCtD
Zidovudine—Malaise—Methotrexate—lymphatic system cancer	0.000172	0.000844	CcSEcCtD
Zidovudine—Vertigo—Methotrexate—lymphatic system cancer	0.000172	0.000841	CcSEcCtD
Zidovudine—Leukopenia—Methotrexate—lymphatic system cancer	0.000171	0.000838	CcSEcCtD
Zidovudine—Cough—Methotrexate—lymphatic system cancer	0.000167	0.000817	CcSEcCtD
Zidovudine—Convulsion—Methotrexate—lymphatic system cancer	0.000166	0.000811	CcSEcCtD
Zidovudine—Arthralgia—Methotrexate—lymphatic system cancer	0.000163	0.000797	CcSEcCtD
Zidovudine—Chest pain—Methotrexate—lymphatic system cancer	0.000163	0.000797	CcSEcCtD
Zidovudine—Myalgia—Methotrexate—lymphatic system cancer	0.000163	0.000797	CcSEcCtD
Zidovudine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000162	0.000791	CcSEcCtD
Zidovudine—Discomfort—Methotrexate—lymphatic system cancer	0.000161	0.000787	CcSEcCtD
Zidovudine—Confusional state—Methotrexate—lymphatic system cancer	0.000157	0.00077	CcSEcCtD
Zidovudine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000156	0.000764	CcSEcCtD
Zidovudine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000153	0.000749	CcSEcCtD
Zidovudine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000153	0.000748	CcSEcCtD
Zidovudine—Skin disorder—Methotrexate—lymphatic system cancer	0.000152	0.000742	CcSEcCtD
Zidovudine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000151	0.000738	CcSEcCtD
Zidovudine—Anorexia—Methotrexate—lymphatic system cancer	0.000149	0.000728	CcSEcCtD
Zidovudine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000142	0.000696	CcSEcCtD
Zidovudine—Insomnia—Methotrexate—lymphatic system cancer	0.000141	0.000691	CcSEcCtD
Zidovudine—Paraesthesia—Methotrexate—lymphatic system cancer	0.00014	0.000686	CcSEcCtD
Zidovudine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000139	0.000681	CcSEcCtD
Zidovudine—Somnolence—Methotrexate—lymphatic system cancer	0.000139	0.000679	CcSEcCtD
Zidovudine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000137	0.000672	CcSEcCtD
Zidovudine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000136	0.000664	CcSEcCtD
Zidovudine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000135	0.000659	CcSEcCtD
Zidovudine—Fatigue—Methotrexate—lymphatic system cancer	0.000135	0.000658	CcSEcCtD
Zidovudine—Pain—Methotrexate—lymphatic system cancer	0.000133	0.000653	CcSEcCtD
Zidovudine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000129	0.000629	CcSEcCtD
Zidovudine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000128	0.000624	CcSEcCtD
Zidovudine—Urticaria—Methotrexate—lymphatic system cancer	0.000124	0.000607	CcSEcCtD
Zidovudine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000123	0.000604	CcSEcCtD
Zidovudine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000123	0.000604	CcSEcCtD
Zidovudine—Asthenia—Methotrexate—lymphatic system cancer	0.000112	0.000548	CcSEcCtD
Zidovudine—Pruritus—Methotrexate—lymphatic system cancer	0.00011	0.00054	CcSEcCtD
Zidovudine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000107	0.000523	CcSEcCtD
Zidovudine—Dizziness—Methotrexate—lymphatic system cancer	0.000103	0.000505	CcSEcCtD
Zidovudine—Vomiting—Methotrexate—lymphatic system cancer	9.92e-05	0.000486	CcSEcCtD
Zidovudine—Rash—Methotrexate—lymphatic system cancer	9.84e-05	0.000482	CcSEcCtD
Zidovudine—Dermatitis—Methotrexate—lymphatic system cancer	9.83e-05	0.000481	CcSEcCtD
Zidovudine—Headache—Methotrexate—lymphatic system cancer	9.78e-05	0.000478	CcSEcCtD
Zidovudine—Nausea—Methotrexate—lymphatic system cancer	9.27e-05	0.000454	CcSEcCtD
